Tafoxiparin is protected by several patent families

Tafoxiparin, Dilafor´s drug product candidate, is protected by several patent families, with basic patent expiries in 2023-2034. A substance patent has been granted in the US, and applications are pending in all major territories for different aspects of the drug product candidate.


As many as 40% of all pregnant women experience protracted labor, which carries a high risk of complications for both mothers and infants.